Edgar Schuck

1.6k total citations
42 papers, 760 citations indexed

About

Edgar Schuck is a scholar working on Molecular Biology, Oncology and Pharmacology. According to data from OpenAlex, Edgar Schuck has authored 42 papers receiving a total of 760 indexed citations (citations by other indexed papers that have themselves been cited), including 17 papers in Molecular Biology, 11 papers in Oncology and 8 papers in Pharmacology. Recurrent topics in Edgar Schuck's work include Computational Drug Discovery Methods (6 papers), Cancer Treatment and Pharmacology (6 papers) and Drug Transport and Resistance Mechanisms (5 papers). Edgar Schuck is often cited by papers focused on Computational Drug Discovery Methods (6 papers), Cancer Treatment and Pharmacology (6 papers) and Drug Transport and Resistance Mechanisms (5 papers). Edgar Schuck collaborates with scholars based in United States, Japan and United Kingdom. Edgar Schuck's co-authors include Hartmut Derendorf, Lakshmi Putcha, Jim Ferry, Christopher DesJardins, Alice Tsai, Marjoleen Nijsen, Y. Nancy Wong, Mark Penney, Jason R. Chan and Mary E. Spilker and has published in prestigious journals such as Journal of Clinical Oncology, Blood and Neurology.

In The Last Decade

Edgar Schuck

42 papers receiving 734 citations

Peers — A (Enhanced Table)

Peers by citation overlap · career bar shows stage (early→late) cites · hero ref

Name h Career Trend Papers Cites
Edgar Schuck United States 18 198 161 148 143 109 42 760
Nancy Van Osselaer Belgium 18 207 1.0× 171 1.1× 207 1.4× 88 0.6× 58 0.5× 30 936
Chien‐Wei Chiang United States 11 286 1.4× 58 0.4× 151 1.0× 99 0.7× 152 1.4× 34 669
Megan Gibbs United States 21 313 1.6× 138 0.9× 300 2.0× 165 1.2× 103 0.9× 46 1.3k
Robert A. Carr United States 19 193 1.0× 92 0.6× 191 1.3× 41 0.3× 65 0.6× 41 986
Venkatesh Pilla Reddy United States 19 325 1.6× 93 0.6× 305 2.1× 48 0.3× 76 0.7× 56 1.1k
Ronald de Vries Belgium 19 302 1.5× 207 1.3× 249 1.7× 89 0.6× 48 0.4× 36 1.5k
Irena Melnikova United States 13 367 1.9× 197 1.2× 56 0.4× 180 1.3× 117 1.1× 22 919
Joan D. Ellis United States 14 129 0.7× 98 0.6× 71 0.5× 132 0.9× 81 0.7× 19 483
Kazutomi Kusano Japan 20 310 1.6× 116 0.7× 241 1.6× 47 0.3× 36 0.3× 46 902
Kyung‐Hoon Lee South Korea 22 339 1.7× 58 0.4× 157 1.1× 66 0.5× 29 0.3× 73 1.4k

Countries citing papers authored by Edgar Schuck

Since Specialization
Citations

This map shows the geographic impact of Edgar Schuck's research. It shows the number of citations coming from papers published by authors working in each country. You can also color the map by specialization and compare the number of citations received by Edgar Schuck with the expected number of citations based on a country's size and research output (numbers larger than one mean the country cites Edgar Schuck more than expected).

Fields of papers citing papers by Edgar Schuck

Since Specialization
Physical SciencesHealth SciencesLife SciencesSocial Sciences

This network shows the impact of papers produced by Edgar Schuck. Nodes represent research fields, and links connect fields that are likely to share authors. Colored nodes show fields that tend to cite the papers produced by Edgar Schuck. The network helps show where Edgar Schuck may publish in the future.

Co-authorship network of co-authors of Edgar Schuck

This figure shows the co-authorship network connecting the top 25 collaborators of Edgar Schuck. A scholar is included among the top collaborators of Edgar Schuck based on the total number of citations received by their joint publications. Widths of edges represent the number of papers authors have co-authored together. Node borders signify the number of papers an author published with Edgar Schuck. Edgar Schuck is excluded from the visualization to improve readability, since they are connected to all nodes in the network.

All Works

20 of 20 papers shown
1.
Geerts, Hugo, Piet H. van der Graaf, Edgar Schuck, et al.. (2023). A combined physiologically‐based pharmacokinetic and quantitative systems pharmacology model for modeling amyloid aggregation in Alzheimer's disease. CPT Pharmacometrics & Systems Pharmacology. 12(4). 444–461. 13 indexed citations
2.
3.
SUGAWARA, Michiko, et al.. (2017). Eribulin shows high concentration and long retention in xenograft tumor tissues. Cancer Chemotherapy and Pharmacology. 80(2). 377–384. 11 indexed citations
4.
Gidal, Barry E., Rama Maganti, Antonio Laurenza, et al.. (2017). Effect of enzyme inhibition on perampanel pharmacokinetics: Why study design matters. Epilepsy Research. 134. 41–48. 23 indexed citations
5.
Wong, Harvey, Tonika Bohnert, Christopher R. Gibson, et al.. (2017). Translational pharmacokinetic-pharmacodynamic analysis in the pharmaceutical industry: an IQ Consortium PK-PD Discussion Group perspective. Drug Discovery Today. 22(10). 1447–1459. 22 indexed citations
6.
7.
Schuck, Edgar, Bhaskar Rege, Antonio Laurenza, et al.. (2017). Predictions of the pharmacokinetic profile of perampanel during pregnancy using physiologically based pharmacokinetic (PBPK) modeling (P3.237). Neurology. 88(16_supplement). 1 indexed citations
8.
Arzimanoglou, Alexis, José Alexandre Ferreira, Andrew Satlin, et al.. (2016). Safety and pharmacokinetic profile of rufinamide in pediatric patients aged less than 4 years with Lennox-Gastaut syndrome: An interim analysis from a multicenter, randomized, active-controlled, open-label study. European Journal of Paediatric Neurology. 20(3). 393–402. 29 indexed citations
9.
Ferraris, Dana, Bridget Duvall, Greg Delahanty, et al.. (2014). Design, Synthesis, and Pharmacological Evaluation of Fluorinated Tetrahydrouridine Derivatives as Inhibitors of Cytidine Deaminase. Journal of Medicinal Chemistry. 57(6). 2582–2588. 45 indexed citations
10.
Schuck, Edgar, et al.. (2013). A Transcellular Assay to Assess the P-gp Inhibition in Early Stage of Drug Development. Drug Metabolism Letters. 6(4). 285–291. 6 indexed citations
11.
Yu, Yanke, et al.. (2013). Characterization of the pharmacokinetics of a liposomal formulation of eribulin mesylate (E7389) in mice. International Journal of Pharmaceutics. 443(1-2). 9–16. 19 indexed citations
12.
Narayan, Sridhar, Hongsheng Cheng, Hong Du, et al.. (2011). Novel second generation analogs of eribulin. Part II: Orally available and active against resistant tumors in vivo. Bioorganic & Medicinal Chemistry Letters. 21(6). 1634–1638. 12 indexed citations
13.
Narayan, Sridhar, Hongsheng Cheng, Hong Du, et al.. (2011). Novel second generation analogs of eribulin. Part III: Blood–brain barrier permeability and in vivo activity in a brain tumor model. Bioorganic & Medicinal Chemistry Letters. 21(6). 1639–1643. 16 indexed citations
14.
Schuck, Edgar, et al.. (2011). Pharmacokinetic characterization of a natural product–inspired novel MEK1 inhibitor E6201 in preclinical species. Cancer Chemotherapy and Pharmacology. 69(1). 229–237. 10 indexed citations
15.
DesJardins, Christopher, et al.. (2010). Interactions between the chemotherapeutic agent eribulin mesylate (E7389) and P-glycoprotein in CF-1 abcb1a-deficient mice and Caco-2 cells. Xenobiotica. 41(4). 320–326. 18 indexed citations
16.
Schmidt, Stephan, Edgar Schuck, Vipul Kumar, Olaf Burkhardt, & Hartmut Derendorf. (2007). Integration of pharmacokinetic/pharmacodynamic modeling and simulation in the development of new anti-infective agents – minimum inhibitory concentration versus time-kill curves. Expert Opinion on Drug Discovery. 2(6). 849–860. 22 indexed citations
17.
Schuck, Edgar & Hartmut Derendorf. (2005). Pharmacokinetic/ pharmacodynamic evaluation of anti-infective agents. Expert Review of Anti-infective Therapy. 3(3). 361–373. 33 indexed citations
18.
19.
Schuck, Edgar, Maria B. Grant, & Hartmut Derendorf. (2005). Effect of Simulated Microgravity on the Disposition and Tissue Penetration of Ciprofloxacin in Healthy Volunteers. The Journal of Clinical Pharmacology. 45(7). 822–831. 17 indexed citations
20.
Schuck, Edgar, et al.. (2004). Physiological, Pharmacokinetic, and Pharmacodynamic Changes in Space. The Journal of Clinical Pharmacology. 44(8). 837–853. 82 indexed citations

Rankless uses publication and citation data sourced from OpenAlex, an open and comprehensive bibliographic database. While OpenAlex provides broad and valuable coverage of the global research landscape, it—like all bibliographic datasets—has inherent limitations. These include incomplete records, variations in author disambiguation, differences in journal indexing, and delays in data updates. As a result, some metrics and network relationships displayed in Rankless may not fully capture the entirety of a scholar's output or impact.

Explore authors with similar magnitude of impact

Breakdown of academic impact, for papers by Nancy Van Osselaer Breakdown of academic impact, for papers by Chien‐Wei Chiang Breakdown of academic impact, for papers by Megan Gibbs Breakdown of academic impact, for papers by Robert A. Carr Breakdown of academic impact, for papers by Venkatesh Pilla Reddy Breakdown of academic impact, for papers by Ronald de Vries Breakdown of academic impact, for papers by Irena Melnikova Breakdown of academic impact, for papers by Joan D. Ellis Breakdown of academic impact, for papers by Kazutomi Kusano Breakdown of academic impact, for papers by Kyung‐Hoon Lee
Rankless by CCL
2026